SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Herc Holdings, Inc. engages in the provision of equipment rental services. It also sells used equipment and contractor supplies, and provides repair, maintenance, equipment management services, safety training, and ancillary services. Its equipment for rent includes aerial, earthmoving, material handling, trucks and trailers, air compressors, compaction, and lighting. The company was founded in 1965 and is headquartered in Bonita Springs, FL.

Herc Holdings Inc

Herc Holdings is seeing increased investor attention as the community evaluates the company's valuation against recent financial performance and broader sector trends. Traders are actively discussing the stock's volatility and potential for a long-term rebound, while monitoring institutional activity and industrial sector shifts for signs of a breakout.

ShapeShift is a decentralized, multichain cryptocurrency platform that empowers users to swap, track, buy, and earn with over 30,000 assets across the top blockchains such as Bitcoin, Ethereum, Dogecoin, Cosmos, and more. The platform emphasizes financial sovereignty and self-custody, providing an open-source environment where users can engage with the most popular crypto tools and services to trade, earn, and hodl their digital assets. FOX token holders can submit and vote on proposals, helping to shape the future of ShapeShift.

ShapeShift FOX Token

ShapeShift FOX token is drawing intense investor attention as community members speculate on its potential for a massive rally, citing low market capitalization and strong utility as reasons to accumulate during market dips. While some users are frustrated by historical price volatility and lack of momentum, many are actively comparing it to other decentralized exchange tokens and calling for long-term holding in anticipation of a broader altcoin market surge.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is currently experiencing heightened volatility as investors weigh speculative excitement over its 11 million TPS performance claims and high-profile industry mentions against concerns regarding recent price drops and low liquidity. Community sentiment is deeply polarized, with some members aggressively accumulating on dips in anticipation of future fiat anchor and partnership announcements, while others remain skeptical, dismissing the project as a pump-and-dump scheme.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending as investors react to the company securing Japan PMDA marketing approval for its Alpha DaRT cancer treatment, a significant regulatory milestone that serves as a global validator for the technology. The community is actively discussing the potential for a U.S. market breakout as the company advances multiple FDA clinical trials, with many bulls interpreting recent price volatility as a favorable accumulation opportunity ahead of anticipated future growth.

Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its brands include QBREXZA, Accutane, Targadox, AMZEEQ, Ximino, ZILXI, Exelderm, and Luxamend. The company was founded by Claude Maraoui in October 2014 and is headquartered in Scottsdale, AZ.

Journey Medical Corp

Journey Medical Corp is trending as investors react to the FDA approval of Emrosi and its upcoming commercial launch in the rosacea market. The community is actively discussing the drug's potential as a new standard of care, alongside ongoing analysis of the company's financial roadmap, insurance coverage progress, and strategic partnership opportunities to drive future revenue.

Global X Funds - Global X DAX Germany ETF

Global X DAX Germany ETF

The $DAX is currently facing significant downward pressure as market participants brace for potential global trade policy shifts and rising geopolitical tensions. The community is actively debating the index's structural integrity, with many technical traders closely monitoring key support levels and pivot points to determine if this is a temporary correction or the start of a broader, more sustained markdown phase.

SKY is a governance token, which is like a digital voting share, for Sky Protocol. This system launched in 2024 as a rebrand and upgrade of the older Maker Protocol. Sky Protocol’s main value lies in giving users a simple, secure way to trade, save, and earn rewards without ever giving up control of their funds. It is built around a stablecoin called USDS, which is always worth one US dollar, but it is completely decentralized.  The protocol is run by automated agreements called smart contracts, so there’s no middleman controlling users' money. The system uses two main tokens: USDS for stable savings, and SKY for community governance. users can help secure the network and earn rewards by staking their SKY tokens in the Staking Engine, which is like locking them in an interest-bearing account to help the system run. The protocol also uses SkyLink to seamlessly connect users' funds across different blockchains for faster and cheaper transactions.  The Sky Protocol is unique because it has no single CEO or traditional core team of investors; instead, it is managed entirely by its global community of SKY token holders. This decentralized setup means that SKY is primarily used for two core utilities: it grants essential voting power to decide on all major system changes, and it can be staked in the Staking Engine to help secure the network and earn rewards. Staking also provides holders with the ability to borrow the USDS stablecoin, making SKY the essential key for both governance and income generation within the ecosystem.

Skycoin

Skycoin is gaining traction as investors discuss its evolving ecosystem, including updates to token buyback programs and its positioning within decentralized finance protocols. Community members are actively sharing perspectives on its long-term potential, with ongoing debate about market performance and its utility compared to established assets.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT is experiencing intense community debate following its recent launch and airdrop, with investors divided between excitement over its privacy-focused technology and skepticism regarding its ties to Cardano and perceived lack of decentralization. Traders are closely monitoring critical support levels while reacting to concerns about potential selling pressure and the project's long-term integration with platforms like Google Cloud.

What is Tron? Tron's mission is to build a truly decentralized internet and aims to be the largest blockchain-based operating system in the world, known as the TRON protocol. The TRON protocol will offer high scalability, high availability, and high throughput computing to serve decentralized applications via smart contracts. Ethereum EVM-based smart contracts will be compatible and deployable on the TRON network as such Solidity developers do not have to rewrite their applications.  Why Tron? Since TRON protocol does not rely on proof of work or mining, instead governed by nodes located around the world, it is decentralized while providing high throughput for transactions on the blockchain. This is suitable for dapps that require high speed transactions especially games. There are a number of tokens already issued on the TRON network and the decentralized exchanges TRX.market has launched.  On July 24th 2018, TRON acquired BitTorrent, one of the largest P2P file sharing protocol. As a result of the acquisition, BitTorrent Token (BTT) was launched as the cryptocurrency to power the economics on the BitTorrent network. The Token will be used to inceltivize file sharing and storage within the network.

Tron

Tron is generating significant community buzz driven by its heavy utilization for global stablecoin transfers and recent ecosystem integrations, including its bridge to the Base network. Investors are actively discussing the potential impact of strategic partnerships with platforms like Rumble and the project's consistent burn mechanics on its long-term market performance.

ConocoPhillips is an exploration and production company, which engages in the exploration, production, transport, and marketing of crude oil, bitumen, and natural gas. It operates through the following geographical segments: Alaska, Lower 48, Canada, Europe, Middle East, and North Africa, Asia Pacific, and Other International. The Alaska segment explores for, produces, transports and markets crude oil, natural gas and NGLs. The Lower 48 segment consists of operations located in the 48 contiguous U.S. states and the Gulf of Mexico. The Canada segment refers to oil sands development in the Athabasca Region of northeastern Alberta and a liquids-rich unconventional play in western Canada. The Europe, Middle East, and North Africa segment includes operations in the Norwegian sector of the North Sea, the Norwegian Sea, Qatar, Libya, Equatorial Guinea and commercial and terminalling operations in the U.K. The Asia Pacific segment focuses on explorations and product operations in China, Indonesia, Malaysia, and Australia. The Other International segment handles exploration activities in Columbia and Argentina. The company was founded by Isaac Elder Blake on November 25, 1875 and is headquartered in Houston, TX.

Conoco Phillips

ConocoPhillips is currently trending as investors monitor the company's aggressive exploration push in the Alaskan Arctic and ongoing strategic integration of Marathon Oil assets. While the community remains focused on potential long-term production growth and LNG opportunities, market sentiment is tempered by broader concerns regarding volatile crude pricing and shifting geopolitical risks affecting the energy sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel...

TD Cowen Boosts Biohaven (NYSE:BHVN) Price Target to $30.00

TD Cowen upped their price objective on Biohaven from $15.00 to $30.00 and gave the stock a "buy" rating in a research note on Wednesday...

<ul class="summary-bullets"><li>Xenon plans to submit a new drug application for azetukalner to the U.S. Food and Drug Administration for the treatment of focal onset seizures in the third quarter of 2026.</li><li>CEO Ian Mortimer said that the trial results “exceeded expectations.”</li><li>Raymond James, meanwhile, kept a ‘Strong Buy’ rating on Biohaven shares following competitor Xenon’s data readout.</li></ul><p><br>Xenon Pharmaceuticals Inc. (XENE) on Monday announced that it has commenced an underwritten public offering of $500 million of its common shares on the heels of the company announcing positive results from a trial of azetukalner in focal onset seizures (FOS).</p><p>The company said that the late-stage study met its primary endpoint of median percent change from baseline in monthly FOS frequency to week 12 in both the 25 mg and 15 mg dose groups compared to a placebo.</p><p>Shares of XENE closed 50% higher in the regular hours of trading.</p><h2 class="st-heading-2">Trial Data</h2><p>With the higher 25 mg dose, a 53.2% median percent change from baseline in monthly FOS frequency was observed, compared with 10.4% for the placebo, the company said.</p><p>Azetukalner also demonstrated a safety and tolerability profile consistent with prior studies, prompting the company to plan submitting a new drug application to the U.S. Food and Drug Administration (FDA) for the treatment of focal onset seizures in the third quarter of 2026.</p><p>CEO Ian Mortimer said that the trial results “exceeded expectations.”</p><p>“Epilepsy is one of the most common neurological diseases, and foundational antiseizure medications do not provide sufficient seizure control for up to 50% of patients, so we are very optimistic about the opportunity for azetukalner to meaningfully shift the epilepsy treatment paradigm,” said CMO Chris Kenney.</p><p>Focal onset seizures, or epilepsy, originate in one localized area of the brain, causing symptoms based on that specific region.</p><h2 class="st-heading-2">Wall Street Reaction</h2><p>Following the trial data announcement, several analysts hiked their price targets on the stock, while also reflecting on the news’ impact on the shares of Biohaven (<a href="https://stocktwits.com/symbol/BHVN">BHVN</a>), which is developing an investigational drug Opakalim for epilepsy, depression, and pain.</p><p>Jefferies raised the firm's price target on Xenon Pharmaceuticals to $100 from $65 and kept a ‘Buy’ rating on the shares. The firm said it thinks azetukalner has the attributes of a top-selling epilepsy pill, driven by best-in-class focal epilepsy data. In 2026, Xenon shares could grind higher as Big Pharma interest rises and as the Street gauges azetuklaner's peak sales potential, the analyst told investors in a research note.</p><p>RBC Capital raised the firm's price target on Xenon Pharmaceuticals to $80 from $59 and kept an ‘Outperform’ rating on the shares, citing a belief that today's "strong" azetukalner data further increases the likelihood that the drug will be approved. The firm, which now estimates 90% odds of success, also sees higher market uptake than previously anticipated and greater potential for the drug to be priced at a premium.</p><h2 class="st-heading-2">Biohaven Still Holds Chance</h2><p>Raymond James, meanwhile, kept a ‘Strong Buy’ rating on Biohaven shares following competitor Xenon’s data readout. Azetukalner showed efficacy in-line with expectations, but with a meaningful safety disadvantage, giving opakalim room to differentiate, it said. The firm believes the results continue to highlight an opportunity for opakalim, or BHV-7000, which has shown meaningful evidence of efficacy with better safety and tolerability.</p><p>Raymond James expects Biohaven to present topline results from the first pivotal trial for opakalim, testing a 25 mg and 50 mg dose, in the second half of 2026, which will more concretely establish the target product profile.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around XENE stock rose from ‘bullish’ to ‘extremely bullish’ over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.</p><p><a href="https://stocktwits.com/symbol/XENE">XENE stock</a> has gained 83% over the past 12 months.</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/vrtx-soars-in-extended-hours-after-experimental-drug-shows-positive-changes-in-autoimmune-kidney-disease/cZdVDGuRIed">VRTX Soars In Extended Hours After Experimental Drug Shows Positive Changes In Autoimmune Kidney Disease</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Biohaven logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

XENE Stock Rallies 50% On Epilepsy Trial Data, But One Analyst Thinks Rival Biohaven Still Has ‘Room To Differentiate’

Xenon said that the late-stage study met its primary endpoint of median percent change from baseline in monthly FOS frequency to week 12 in both the 25 mg and 15 mg dose groups compared to placebo.

Equity

Xenon said that the late-stage study met its primary endpoint of median percent change from baseline in monthly FOS frequency to week 12 in both the 25 mg and 15 mg dose groups compared to placebo.


Biohaven (NYSE:BHVN) Shares Gap Up - Time to Buy?

Biohaven (NYSE:BHVN) Shares Gap Up - Here's Why...

TD Asset Management Inc Cuts Stake in Biohaven Ltd. $BHVN

TD Asset Management Inc lowered its stake in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) by 53.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The...

Biohaven (NYSE:BHVN) Given New $10.00 Price Target at HC Wainwright

HC Wainwright dropped their price objective on shares of Biohaven from $11.00 to $10.00 and set a "neutral" rating on the stock in a research note on Wednesday...

Biohaven (NYSE:BHVN) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Royal Bank Of Canada increased their price objective on shares of Biohaven from $22.00 to $23.00 and gave the company an "outperform" rating in a research report on Tuesday...

JPMorgan Chase & Co. Reduces Stake in Biohaven Ltd. $BHVN

JPMorgan Chase & Co. reduced its stake in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) by 48.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange...

Biohaven (NYSE:BHVN) Posts Earnings Results, Beats Expectations By $0.32 EPS

Biohaven (NYSE:BHVN - Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22...

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial...

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Current Price	$8.93
Prev Close	$8.96
Open	$8.90
Dividend Yield	0.00%
50-Day Moving Average	$11.31
Beta	1.63
Avg. Volume	2.18M
PE Ratio	-1.28

52-Week High	$31.18
52-Week Low	$7.48
Market Capitalization	$1.34B
EPS (Annual)	-$6.86
Price to Book	22.77
Revenue Per Employee	$0.00

BHVN
Biohaven Pharmaceutical Holding Company Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BHVN News

BHVNBiohaven Pharmaceutical Holding Company Ltd